Serum TGF-β1 and CD14 Predicts Response to Anti-TNF-α Therapy in IBD
Authors:
- Stepan CoufalSCStepan Coufal
- Miloslav KverkaMKMiloslav Kverka
- Jakub KreisingerJKJakub Kreisinger
- Tomas ThonTTTomas Thon
- Filip RobFRFilip Rob
- Martin KolarMKMartin Kolar
- Zuzana ReissZRZuzana Reiss
- Dagmar SchierovaDSDagmar Schierova
- Klara KostovcikovaKKKlara Kostovcikova
- Radka RoubalovaRRRadka Roubalova
- Zuzana JackovaZJZuzana Jackova
Open Access
- 20 June 2023
- journal article
- research article
- Published by Wiley in Journal of Immunology Research
- Vol. 2023, 1-16
Abstract
Background. Tumor necrosis factor-alpha (TNF-α) agonists revolutionized therapeutic algorithms in inflammatory bowel disease (IBD) management. However, approximately every third IBD patient does not respond to this therapy in the long term, which delays efficient control of the intestinal inflammation. Methods. We analyzed the power of serum biomarkers to predict the failure of anti-TNF-α. We collected serum of 38 IBD patients at therapy prescription and 38 weeks later and analyzed them with relation to therapy response (no-, partial-, and full response). We used enzyme-linked immunosorbent assay to quantify 16 biomarkers related to gut barrier (intestinal fatty acid-binding protein, liver fatty acid-binding protein, trefoil factor 3, and interleukin (IL)-33), microbial translocation, immune system regulation (TNF-α, CD14, lipopolysaccharide-binding protein, mannan-binding lectin, IL-18, transforming growth factor-β1 (TGF-β1), osteoprotegerin (OPG), insulin-like growth factor 2 (IGF-2), endocrine-gland-derived vascular endothelial growth factor), and matrix metalloproteinase system (MMP-9, MMP-14, and tissue inhibitors of metalloproteinase-1). Results. We found that future full-responders have different biomarker profiles than non-responders, while partial-responders cannot be distinguished from either group. When future non-responders were compared to responders, their baseline contained significantly more TGF-β1, less CD14, and increased level of MMP-9, and concentration of these factors could predict non-responders with high accuracy (AUC0.938). Interestingly, during the 38 weeks, levels of MMP-9 decreased in all patients, irrespective of the outcome, while OPG, IGF-2, and TGF-β1 were higher in non-responders compared to full-responders both at the beginning and the end of the treatment. Conclusions. The TGF-β1 and CD14 can distinguish non-responders from responders. The changes in biomarker dynamics during the therapy suggest that growth factors (such as OPG, IGF-2, and TGF-β) are not markedly influenced by the treatment and that anti-TNF-α therapy decreases MMP-9 without influencing the treatment outcome.Keywords
Funding Information
- Ministerstvo Zdravotnictví Ceské Republiky (NV18-09-00493, NV18-05-00394, 61388971, LQ200202105)
- Institute of Microbiology, Chinese Academy of Sciences (NV18-09-00493, NV18-05-00394, 61388971, LQ200202105)
- Czech Academy of Sciences (NV18-09-00493, NV18-05-00394, 61388971, LQ200202105)
This publication has 93 references indexed in Scilit:
- LPS‐binding Protein Enables Intestinal Epithelial Restitution Despite LPS ExposureJournal of Pediatric Gastroenterology and Nutrition, 2012
- Mannan-binding lectin deficiency in pediatric patients with inflammatory bowel diseaseScandinavian Journal of Gastroenterology, 2011
- Interleukin-33 expression is specifically enhanced in inflamed mucosa of ulcerative colitisJournal of Gastroenterology, 2010
- Epithelial-derived IL-33 and its receptor ST2 are dysregulated in ulcerative colitis and in experimental Th1/Th2 driven enteritisProceedings of the National Academy of Sciences, 2010
- Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitisGut, 2009
- Dual Role of Lipopolysaccharide (LPS)-Binding Protein in Neutralization of LPS and Enhancement of LPS-Induced Activation of Mononuclear CellsInfection and Immunity, 2001
- Mannan-binding lectin (MBL) gene polymorphisms in ulcerative colitis and Crohn’s diseaseGenes & Immunity, 2001
- Mannose-binding lectin: the pluripotent molecule of the innate immune systemImmunology Today, 1996
- Coated Oral 5-Aminosalicylic Acid Therapy for Mildly to Moderately Active Ulcerative ColitisNew England Journal of Medicine, 1987
- A SIMPLE INDEX OF CROHN'S-DISEASE ACTIVITYThe Lancet, 1980